A new trading day began on Monday, with Summit Therapeutics Inc (NASDAQ: SMMT) stock price up 4.48% from the previous day of trading, before settling in for the closing price of $17.87. SMMT’s price has ranged from $2.10 to $33.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -28.65% over the last five years. Meanwhile, its annual earnings per share averaged 70.62%. With a float of $114.59 million, this company’s outstanding shares have now reached $737.09 million.
The firm has a total of 105 workers. Let’s measure their productivity. In terms of profitability, gross margin is 385.96%, operating margin of 77226.38%, and the pretax margin is 83760.85%.
Summit Therapeutics Inc (SMMT) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Summit Therapeutics Inc is 84.45%, while institutional ownership is 11.49%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.62% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Here are Summit Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Analysing the last 5-days average volume posted by the [Summit Therapeutics Inc, SMMT], we can find that recorded value of 3.27 million was lower than the volume posted last year of 3.44 million. As of the previous 9 days, the stock’s Stochastic %D was 59.26%. Additionally, its Average True Range was 1.25.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 39.14%, which indicates a significant decrease from 68.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.41% in the past 14 days, which was lower than the 114.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.50, while its 200-day Moving Average is $12.20. Now, the first resistance to watch is $19.18. This is followed by the second major resistance level at $19.69. The third major resistance level sits at $20.47. If the price goes on to break the first support level at $17.88, it is likely to go to the next support level at $17.10. Now, if the price goes above the second support level, the third support stands at $16.59.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
With a market capitalization of 13.76 billion, the company has a total of 737,448K Shares Outstanding. Currently, annual sales are 0 K while annual income is -614,930 K. The company’s previous quarter sales were 0 K while its latest quarter income was -56,250 K.
